Ben Osborn, British Pharmaceutical Industry
Ben Osborn (pictured), UK Country Manager of Pfizer, is the new President of the Association of the British Pharmaceutical Industry, replacing Hasseb Ahmad. In addition, Pinder Sahota, General Manager of Novo Nordisk, has been appointed VP.
Kate Mingay, Richard Gilkes and Tim Doggett, Chemical Business Association
The Chemical Business Association (CBA), which represents the UK chemical supply chain, has elected Kate Mingay, MD of Dakram Materials, as chair for a two-year term. Richard Gilkes, MD of Stort Chemicals was elected VC. In addition, Tim Doggett has been appointed CEO, following the retirement of Peter Newport.
Roger Perlmutter, Eikon Therapeutics
US biopharmaceutical startup, Eikon Therapeutics, which develops live-cell resolution microscopy and engineering for drug discovery, has appointed former president of Merck Research Laboratories Roger Perlmutter as CEO.
Thorsten Graef and Michael Brock, Acepodia
US biotechnology company Acepodia, headquartered in San Mateo, CA, has appointed Thorsten Graef as CMO. Graef brings over 10 years’ experience as a global drug development leader, most recently at AbbVie where he was VP of oncology early development. In addition, Michael Brock has been appointed as Chief Strategy Officer. Brock joins the company from Wells Fargo Securities’ Healthcare Investment Banking where he was a MD responsible for biopharmaceutical companies.
Mark Timney, Attralus Therapeutics
US biopharmaceutical company Attralus Therapeutics has appointed Mark Timney as CEO and a member of its board. Timney has over 30 years’ leadership experience in global biopharmaceutical companies, most recently as CEO of The Medicines Company.
Michael Stocum, Bantam Pharmaceutical
US oncology drug discovery and development firm Bantam Pharmaceutical, headquartered in Boston, MA, has appointed Michael Stocum as CEO and President. He succeeds Mike Luther who will stay on as an adviser to the company.
Angelo Pugliese and Duncan McArthur, BioAscent
UK provider of integrated drug discovery services BioAscent, based in Newhouse, Scotland, has appointed Angelo Pugliese as Associate Director to lead the company’s computational chemistry service. In addition, Duncan McArthur becomes Associate Director of the medical chemistry team.
Percy Carter, Blueprint Medicines
US global precision therapy company Blueprint Medicines, which develops medicines for cancer and haematologic disorders, has appointed FibroGen’s Percy Carter as CSO. Carter brings more than 20 years’ global leadership in pharmaceutical companies and industry experience.
Swati Tole, Capsida
US gene therapy company Capsida has appointed Swati Tole to the new role of CMO. Tole joins the company from Genentech, where she was VP of clinical development.
Antoine Yver, Centessa Pharmaceuticals
US-headquartered Centessa Pharmaceuticals has appointed Antoine Yver as CMO. Yver, with over than 30 years’ experience in the global pharmaceutical industry, joins the company from Daiichi Sankyo, where he served as executive VP and Global Head, R&D oncology, and Chair of the cancer enterprise.
Indro Mukerjee, Innovate UK
Technology business leader Indro Mukerjee has been appointed CEO of Innovate UK, the UK’s innovation agency, replacing interim CEO Ian Campbell. Mukerjee was previously CEO at insurance outsourcer Watchstone. He has also led venture capital-backed companies and spinouts, including Plastic Logic and C-MAC MicroTechnology.
Luisa Salter-Cid, Flagship Pioneering
Gossamer Bio’s CSO Luisa Salter-Cid has joined US venture capital company Flagship Pioneering as CSO of its pioneering medicines division.
Dan Lynch, GV
Biotechnology veteran Dan Lynch has been appointed to GV, the venture-capital arm of Google parent Alphabet, as an Executive Venture Partner and Senior Member of the life sciences team.
Paul K. Audhya, KalVista Pharmaceuticals
US pharmaceuticals company KalVista Pharmaceuticals, which focuses on small molecule protease inhibitors, has appointed Paul K. Audhya as CMO. Audhya joins the company from Arena Pharmaceuticals, where he was senior VP of global medical affairs. He has over 20 years’ experience of clinical development and global medical affairs across a range of therapeutic areas, including rare diseases.
Yizhe Wang, LianBio
Chinese drug licensing company LianBio, headquartered in Shanghai, has appointed Yizhe Wang as CEO. Wang joins LianBio from Eli Lilly, where he was Global Brand Development Leader for Lilly Oncology. Wang also joins the board.
Tara O’Meara, Relay Therapeutics
US precision medicine company Relay Therapeutics has appointed Tara O’Meara as senior VP of clinical development operations, and AstraZeneca’s Charles Ferté as VP, global medical lead for RLY-4008. O’Meara joins the company from bluebird bio where she led the clinical development operations department.
Pritesh Gandhi, TellBio
US biotechnology services provider TellBio has appointed Pritesh Gandhi as CEO and Annie Partisano as senior VP and Head of Operations. Gandhi joins TellBio from Alnylam Pharmaceuticals, where he was General Manager. Partisano most recently worked at Kiniksa Pharmaceuticals as VP, medical operations.
Josh Bilenker and Jeff Engelman, Treeline Biosciences
Josh Bilenker and Jeff Engelman have joined forces to create a cancer biotechnology company, Treeline Biosciences. Bilenker becomes the CEO and Engelman the CSO of the new company.
Marc Stapley, Veracyte
Genomic diagnostics company Veracyte has appointed Helix’s CEO Marc Stapley to succeed its Chief Executive and Co-founder Bonnie Anderson. Anderson will assume the role of Executive Chair and act as an adviser to Stapley for ‘the next few years’. Stapley will join the company’s board.